Tg3647 mice over-express human TNF that leads to the gradual development of spontaneous slow progressing chronic inflammatory polyarthritis with 100% penetrance.
Collagen antibody-induced arthritis (CAIA) is a simple mouse model of rheumatoid arthritis that can be used to address questions relating to the pathogenic mechanisms of the disease and serves as a platform for the evaluation of candidate therapeutic agents.
Biomedcode has standardized the model in
- C57BL/6 wild type mice,
- Mice humanized for hTNFR1
- Tg1278TNFKO human TNF transgenic mice
- Mice humanized for both TNF and TNFR1
and developed platforms to allow the evaluation of different arthritis therapeutics.
TgA86 mice overexpress mouse transmembrane TNF from a Δ1-12 mTNF-globin transgene. They develop with 100% incidence peripheral and axial joint pathology accompanied by new bone formation features, all characteristic of human SpA pathology.
Tg54531 is a transgenic mouse with transmembrane human TNF deregulated expression resulting in the spontaneous development of arthritis pathology that closely resembles human rheumatoid arthritis.
The mice develop arthritis with 100% penetrance and provide a fast in-vivo model for evaluating human therapeutics targeting rheumatoid arthritis.
The Tg5453 mouse model was successfully used in establishing the therapeutic efficacy of Remicade®, the first anti-TNF therapeutic to be successfully applied in the clinic, and is currently used for screening anti-rheumatoid candidate drugs.
Biomedcode’s human TNF transgenic arthritis model, (Tg197), contributes to the non-clinical assessment of adalimumab biosimilar GP2017 with originator Humira. Read More
Biomedcode’s human TNF transgenic arthritis model, (Tg197), contributes to the non-clinical assessment of etanercept biosimilar GP2015 with originator etanercept (Enbrel).
Published in Expert Opinion on Biological Therapy 2016 Vol. 16 , Iss. 10, 1185-1195.
Read More